SCHEMBL19690891

SCHEMBL19690891

C=CCNc1cccc2nc(Nc3ccccc3)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.44
MEN1 O00255 6/20 0.44
KDM4E B2RXH2 4/20 0.44
MAPT P10636 4/20 0.44
RAB9A P51151 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALPG P10696 1/20 0.44
ALDH1A1 P00352 2/20 0.42
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
SUMO3 P55854 1/20 0.41
SUMO2 P61956 1/20 0.41
SUMO1 P63165 1/20 0.41
RHOA P61586 1/20 0.40
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TSHR P16473 2/20 0.39
HSD17B10 Q99714 2/20 0.39
GLA P06280 2/20 0.39
NPY1R P25929 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10865574 0.76 KMT2A (0.47) KMT2AMEN1KDM4EMAPTRAB9A
SCHEMBL19690955 0.75 SETDB1 (0.54) KMT2AMEN1KDM4EMAPTRAB9A
SCHEMBL1850351 0.74 KMT2A (0.45) KMT2AMEN1KDM4EMAPTRAB9A
SCHEMBL4105441 0.73 RAB9A (0.42) KMT2AMEN1KDM4EMAPTRAB9A
SCHEMBL19691017 0.71 SETDB1 (0.59) KMT2AMEN1KDM4EMAPTRAB9A
SCHEMBL896623 0.71 KMT2A (0.59) KMT2AMEN1KDM4EMAPTRAB9A
SCHEMBL31497264 0.71 KMT2A (0.59) KMT2AMEN1KDM4EMAPTRAB9A
SCHEMBL17629029 0.71 MEN1 (0.53) KMT2AMEN1KDM4EMAPTRAB9A
SCHEMBL396525 0.70 NCF1 (0.61) KMT2AMEN1KDM4EMAPTRAB9A
SCHEMBL29833517 0.70 NCF1 (0.61) KMT2AMEN1KDM4EMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9980954-B2 Quinoline derivatives for inhibiting histone methyltransferases and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-29 US claimed
US-20170354650-A1 QUINOLINE DERIVATIVES FOR INHIBITING HISTONE METHYLTRANSFERASES AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2017-12-14 US claimed
US-9980954-B2 Quinoline derivatives for inhibiting histone methyltransferases and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-05-29 US disclosed
US-20170354650-A1 QUINOLINE DERIVATIVES FOR INHIBITING HISTONE METHYLTRANSFERASES AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170354650-A1 QUINOLINE DERIVATIVES FOR INHIBITING HISTONE METHYLTRANSFERASES AND USE THEREOF NSD1, EHMT1, SETDB1 KMT2A 17/4885MEN1 1806/4885KDM4E 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.